Category

UF Innovate | Accelerate

Florida Institute and MPWRM Resource Center Fund Amend Surgical

UF Innovate | Sid Martin Biotech alum Amend Surgical, Inc., an Alachua-based medical device company, announced that it has finalized a funding agreement with the Institute for Commercialization of Florida Technology (the Florida Institute) along with being awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center.

DHS Announces Cooling Solutions Prize Challenge Finalists in Celebration of Earth Day

UF startup Micro Nano Technologies, announced as finalists in the Cooling Solutions Challenge prize competition. Launched in September 2021, by DHS Science and Technology Directorate (S&T) and the Federal Emergency Management Agency (FEMA), this $195,000 prize competition marks the first in a series focusing on national climate resilience.

Satlantis, LLC, Announces Strategic Investment

UF startup Satlantis, LLC ("Satlantis"), a US technology leader in high precision miniaturized satellites and cameras is pleased to announce a strategic investment from Encino Environmental Holdings, LLC ("Encino"). This investment will allow Satlantis to accelerate the commercialization of its satellite-based greenhouse gas (GHG) monitoring technology and develop new products and services for the North American market.

1000X More Efficient Neural Networks: Building an Artificial Brain With 86 Billion Physical (but Not Biological) Neurons

What if in our attempt to build artificial intelligence we don’t simulate neurons in code and mimic neural networks in Python, but instead build actual physical neurons connected by physical synapses in ways very similar to our own biological brains? That’s precisely what UF startup Rain Neuromorphics, is trying to do: build a non-biological yet very human-style artificial brain.

Lacerta Therapeutics Expands Executive Leadership Team

UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.